Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Eradication of Nontuberculous Mycobacteria in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Cohort Study
Vered Wiesel, Micha Aviram, Meir Mei‐Zahav, et al.
Journal of Cystic Fibrosis (2023) Vol. 23, Iss. 1, pp. 41-49
Closed Access | Times Cited: 19

Showing 19 citing articles:

Cystic fibrosis
Marcus Mall, Pierre‐Régis Burgel, Carlo Castellani, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 11
The complexities of elexacaftor/tezacaftor/ivacaftor therapeutic drug monitoring in a person with cystic fibrosis and Mycobacterium abscessus pulmonary disease
Claire Y Mou, Daniel Henderson, A. Matson, et al.
European Clinical Respiratory Journal (2025) Vol. 12, Iss. 1
Open Access
Growing from common ground: nontuberculous mycobacteria and bronchiectasis
Eva Van Braeckel, Cédric Bosteels
European Respiratory Review (2024) Vol. 33, Iss. 173, pp. 240058-240058
Open Access | Times Cited: 4
Clinical and radiological improvement of cavitary Mycobacteroides abscessus disease in cystic fibrosis following initiation of elexacaftor/tezacaftor/ivacaftor
Roderick Gavey, J D Nolan, Vanessa Moore, et al.
Journal of Cystic Fibrosis (2024) Vol. 23, Iss. 5, pp. 1024-1026
Open Access | Times Cited: 3
Cystic fibrosis year in review 2023
David V. Swetland, Adrienne P. Savant
Pediatric Pulmonology (2024) Vol. 59, Iss. 12, pp. 3106-3116
Open Access | Times Cited: 3
Druggable redox pathways against Mycobacterium abscessus in cystic fibrosis patient-derived airway organoids
Stephen Adonai Leon‐Icaza, Salimata Bagayoko, Romain Vergé, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 8, pp. e1011559-e1011559
Open Access | Times Cited: 9
Trials and tribulations of highly effective modulator therapies in cystic fibrosis
Nathan Lieu, Bernadette Prentice, Penelope Field, et al.
Paediatric Respiratory Reviews (2023) Vol. 48, pp. 10-19
Closed Access | Times Cited: 7
Nontuberculous Mycobacterial Pulmonary Disease: Patients, Principles, and Prospects
Minh-Vu H. Nguyen, Michelle Haas, Shannon H. Kasperbauer, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 4, pp. e27-e47
Closed Access | Times Cited: 1
Prospective evaluation of nontuberculous mycobacteria disease in cystic fibrosis: The design of the PREDICT study
Stacey L. Martiniano, Silvia M. Caceres, Katie R. Poch, et al.
Journal of Cystic Fibrosis (2023) Vol. 23, Iss. 1, pp. 50-57
Open Access | Times Cited: 3
Nonantibiotic Management of Nontuberculous Mycobacteria in Non–Cystic Fibrosis Bronchiectasis: Natural or Nonsense?
Katherine B. Hisert, Jerry A. Nick
Annals of the American Thoracic Society (2024) Vol. 21, Iss. 4, pp. 543-545
Open Access
Non-Tuberculous Mycobacterial Infection in Cystic Fibrosis Before and after Initiation of Elexacaftor-Tezacaftor-Ivacaftor: Now is Not the Time to Lower the Guard
Ieuan Evans, Daniel J. Smıth, David W. Reid
(2024)
Closed Access
Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis with Mildly Decreased and Normal Lung Function: A Real-Life Observational Study
Karin Yaacoby‐Bianu, Adi Dagan, Malena Cohen‐Cymberknoh, et al.
Annals of the American Thoracic Society (2024) Vol. 21, Iss. 11, pp. 1620-1623
Closed Access
The novel drug candidate VOMG kills Mycobacterium abscessus and other pathogens by inhibiting cell division
Giulia Degiacomi, Laurent R. Chiarelli, Olga Riabova, et al.
International Journal of Antimicrobial Agents (2024) Vol. 64, Iss. 4, pp. 107278-107278
Open Access
Nontuberculous Mycobacteria Pulmonary Infection in Children with Cystic Fibrosis
Sabiha R. Hussain, Amira M. Said, Jeffrey R. Starke
Current Infectious Disease Reports (2024) Vol. 26, Iss. 10, pp. 217-226
Closed Access
The ageing of people living with cystic fibrosis: what to expect now?
Almudena Felipe Montiel, Antonio Álvarez Fernández, Mario Culebras Amigo, et al.
European Respiratory Review (2024) Vol. 33, Iss. 174, pp. 240071-240071
Open Access
Highly Effective Modulator Therapy: Implications for the Microbial Landscape in Cystic Fibrosis
Kristina N. Valladares, L. Jones, Jarrod W. Barnes, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 22, pp. 11865-11865
Open Access
One year of ETI reduces lung bacterial colonisation in adults with cystic fibrosis
Lucile Mianowski, Anne Doléans-Jordheim, Luc Barraud, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CFTR-modulator therapy
Justyna Milczewska, Zulfiya Syunyaeva, Aleksandra Żabińska-Jaroń, et al.
European Respiratory Review (2024) Vol. 33, Iss. 174, pp. 240068-240068
Open Access
ERS International Congress 2023: highlights from the Respiratory Infections Assembly
Francesco Bindo, Giovanni Fumagalli, Kiarina Chichirelo-Konstantynovych, et al.
ERJ Open Research (2023) Vol. 10, Iss. 3, pp. 00880-2023
Open Access | Times Cited: 1
Page 1

Scroll to top